56 results
Search Results
2. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent
3. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
4. Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species
5. Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients
6. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl
7. Pharmacokinetics of Dietary Phenethyl Isothiocyanate in Rats
8. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent
9. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents
10. Study of the pharmacokinetics of vancomycin in patients with impaired liver function
11. Lack of interaction between meloxicam and warfarin in healthy volunteers
12. Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients
13. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration
14. Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man
15. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man
16. Pharmacokinetics of total and free valproic acid during monotherapy in infants
17. Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis
18. Effect of uranyl nitrate-induced acute renal failure on the pharmacokinetics of sulfobromophthalein in rats
19. Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man
20. Plasma and cerebrospinal fluid concentrations of indomethacin in humans: Relationship to analgesic activity
21. Pharmacokinetics of antibiotics in critically ill patients
22. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction
23. Disopyramide pharmacokinetics in patients with acute myocardial infarction
24. Individual variation in the response to phenprocoumon
25. Pharmacokinetics of naproxen in subjects with normal and impaired renal function
26. Pharmacokinetics of ketanserin in man
27. Pharmacokinetics of intravenous and oral tolmesoxide
28. Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee
29. Pharmakokinetische Bedeutung der Proteinbindung
30. Naproxen disposition in patients with alcoholic cirrhosis
31. Cefodizime penetration into skin suction blister fluid following a single intravenous dose
32. Pharmacokinetics of nitrendipine in terminal renal failure
33. Bromocriptine concentration in saliva and plasma after long-term treatment of patients with Parkinson's disease
34. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure
35. Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding
36. Pharmacokinetics of furosemide in anephric patients and in normal subjects
37. Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver
38. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator
39. Melphalan concentration dependent plasma protein binding in healthy humans and rats
40. Pharmacokinetics and distribution of flucloxacillin in pacemaker patients
41. Transsynovial distribution and protein binding of pirazolac in patients with rheumatoid arthritis
42. Cirrhosis of the liver markedly impairs the elimination of mexiletine
43. The protein binding of methotrexate by the serum of normal subjects
44. Non-linear elimination and protein binding of probenecid
45. Bioavailability and elimination of nitrendipine in liver disease
46. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure
47. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease
48. Pharmacokinetics of chlorpropamide in epileptic patients: Effects of enzyme induction and urine pH on chlorpropamide elimination
49. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva
50. Effect of probenecid on the elimination and protein binding of ceftriaxone
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.